受血糖监测仪需求强劲推动,Dexcom上调年度营收预期

路透中文
Jul 31
受血糖监测仪需求强劲推动,Dexcom上调年度营收预期

路透7月30日 - 医疗设备制造商德克斯康(Dexcom, DXCM.O周四上调了全年营收预期,并超出了市场对该季度业绩的预期, 这得益于 其用于监测血糖水平的连续血糖监测仪需求持续强劲 ,推动该公司股价在盘后交易中上涨逾4%。

详情如下:

  • 随着糖尿病护理意识的提高、保险覆盖范围的扩大,以及消费者日益倾向于采用无需指尖采血的技术,对连续血糖监测仪的需求不断增长,这加剧了市场领导者德康(Dexcom)、美敦力(Medtronic, MDT.N)和雅培实验室(Abbott Laboratories, ABT.N)之间的竞争。

  • Dexcom公布第二季度营收为13.1亿美元,较上年同期增长13%。伦敦证券交易所集团(LSEG)汇编的数据,分析师此前平均预期为12.9亿美元。

  • 该公司公布季度经调整后每股收益为70美分,高于市场预期的61美分。

  • 该公司预计全年营收将在51.8亿美元至52.5亿美元之间,此前预测区间为51 .6亿美元 至52.5亿美元,而分析师的预期为52.2亿美元。

  • Dexcom 于 5 月表示,将与激进投资者埃利奥特投资管理公司(Elliott Investment Management)合作,任命两名独立董事并重组一个关键的董事会委员会

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10